Home›Trial›NCT06294236
🔬NCT06294236Phase 1ACTIVE NOT RECRUITING

Study Evaluating SC291 in Subjects With Severe r/r B-cell Mediated Autoimmune Diseases (GLEAM)

Study Summary

SC291-102 is a Phase 1 study to evaluate SC291 safety and tolerability, preliminary clinical response, cellular kinetics and exploratory assessments for subjects with severe autoimmune diseases.

Conditions
Lupus ErythematosusSystemic Lupus ErythematosusSLE (Systemic Lupus)Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisGranulomatous PolyangiitisMicroscopic Polyangiitis
Interventions / Drugs
SC291
View on ClinicalTrials.gov ↗
Sponsor
SANA
Sana Biotechnology
Cell Engineering
D41/100
Study Details
Enrollment7 participants
Primary Completion—
Lead SponsorSana Biotechnology
Data Retrieved2026-04-11 04:26:45.208860+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.